div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: APPLICATION NUMBER: 125083Orig1s000 · 2011 9 16 · Hoffiann-La Roche HLR has submitted this original BLA relating to the combination use of pegylated interferon alfa-2a Pegasys src=https:reader035fdocumentsinreader035viewer20220716056140e01983382e045471baaahtml5thumbnails1jpg width=142 height=106 layout=responsive amp-img divpCENTER FOR DRUG EVALUATION AND RESEARCHp pAPPLICATION NUMBER: 125083Orig1s000p pOFFICE DIRECTOR MEMOpdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: APPLICATION NUMBER: 125083Orig1s000 · 2011 9 16 · Hoffiann-La Roche HLR has submitted this original BLA relating to the combination use of pegylated interferon alfa-2a Pegasys src=https:reader035fdocumentsinreader035viewer20220716056140e01983382e045471baaahtml5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: APPLICATION NUMBER: 125083Orig1s000 · 2011 9 16 · Hoffiann-La Roche HLR has submitted this original BLA relating to the combination use of pegylated interferon alfa-2a Pegasys src=https:reader035fdocumentsinreader035viewer20220716056140e01983382e045471baaahtml5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdiv